These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1444 related items for PubMed ID: 30464691

  • 1. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A, Sattar J, Sahai V, Baetz T, Lakoff JM.
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
    Sattar J, Kartolo A, Hopman WM, Lakoff JM, Baetz T.
    J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
    [Abstract] [Full Text] [Related]

  • 3. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.
    JAMA Oncol; 2019 Mar 01; 5(3):376-383. PubMed ID: 30589930
    [Abstract] [Full Text] [Related]

  • 6. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar 01; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 7. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun 01; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 8. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul 01; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 9. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N.
    BMC Cancer; 2019 Oct 21; 19(1):974. PubMed ID: 31638948
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The impact of corticosteroid use during anti-PD1 treatment.
    Pan EY, Merl MY, Lin K.
    J Oncol Pharm Pract; 2020 Jun 21; 26(4):814-822. PubMed ID: 31495293
    [Abstract] [Full Text] [Related]

  • 14. Multiple sclerosis outcomes after cancer immunotherapy.
    Garcia CR, Jayswal R, Adams V, Anthony LB, Villano JL.
    Clin Transl Oncol; 2019 Oct 21; 21(10):1336-1342. PubMed ID: 30788836
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
    Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A.
    J Endocrinol Invest; 2020 Mar 21; 43(3):337-345. PubMed ID: 31542865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M.
    J Cancer Res Clin Oncol; 2019 Feb 21; 145(2):511-521. PubMed ID: 30539281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.